131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy
Rahul V. Parghane, Sanjay Talole, Sandip Basu
Topics & Concepts
MedicineRadionuclide therapyInternal medicineProgressive diseaseNeuroendocrine tumorsResponse Evaluation Criteria in Solid TumorsSomatostatin receptorOctreotideProgression-free survivalNuclear medicineOncologyGastroenterologySomatostatinDiseaseOverall survivalAdrenal and Paraganglionic TumorsCancer, Hypoxia, and MetabolismNeuroendocrine Tumor Research Advances